Check Cap (CHEK) Shares Up 0% on Analyst Upgrade

Check Cap Ltd (NASDAQ:CHEK) shot up 0% on Thursday after HC Wainwright raised their price target on the stock from $5.50 to $6.00. HC Wainwright currently has a buy rating on the stock. Check Cap traded as high as $1.02 and last traded at $0.93. 1,504,361 shares traded hands during trading, an increase of 226% from the average session volume of 460,983 shares. The stock had previously closed at $0.93.

CHEK has been the topic of a number of other reports. Maxim Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Check Cap in a research note on Wednesday, September 27th. Zacks Investment Research raised shares of Check Cap from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Check Cap presently has a consensus rating of “Hold” and an average target price of $4.75.

An institutional investor recently raised its position in Check Cap stock. Sabby Management LLC grew its position in Check Cap Ltd (NASDAQ:CHEK) by 467.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the quarter. Check Cap makes up about 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th largest position. Sabby Management LLC owned 8.36% of Check Cap worth $2,724,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 18.97% of the company’s stock.

The firm has a market capitalization of $15.74 and a P/E ratio of -1.52.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/check-cap-chek-shares-up-0-on-analyst-upgrade.html.

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply